Replies to post #196604 on Biotech Values

[DewDiligence]

Re: ABBV's HCV guidance

In the CC Q&A, Rick Gonzalez (CEO) said the end-2015 V-Pak run rate will be close to the original guidance and might still hit the guidance, but his best guess is that they will come in a little short.

Gonzalez also emphasized that ABBV's 2016 HCV sales will be larger than 2015 as V-Pak is launched in Japan and additional EU countries.